Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Lupus ; 24(14): 1479-85, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26163661

ABSTRACT

OBJECTIVES: Pericardial involvement is a frequent manifestation of systemic lupus erythematosus (SLE). Growing evidence suggests that colchicine may be useful for acute or recurrent pericarditis. We report for the first time a series of 10 consecutive cases of SLE with pericarditis treated with colchicine. METHODS: Inclusion criteria in this retrospective study were diagnosis of SLE, pericarditis and receiving colchicine. RESULTS: We included 10 consecutive cases of SLE with pericarditis treated with colchicine (nine women, mean age at the index pericarditis 35 ± 12 years). Pericarditis was the initial manifestation of SLE for two patients, whereas eight patients had SLE lasting for a median of 2.5 years (15 days to 13 years) and had received prednisone (n = 7, 2-30 mg/d), hydroxychloroquine (n = 7), azathioprine (n = 3), methotrexate (n = 2), and mycophenolate mofetil (n = 1). For six patients, pericarditis was associated with other SLE manifestations. Altogether, colchicine avoided the use (n = 2) or increase in dosage (n = 5) of steroids in seven cases; the increase in steroids dosage was minimal for two patients. Colchicine 1 mg was given for a median of 39 days (10 days to 54 months). Symptoms completely resolved after a median of 2.5 days (1-30 days) after initiation of colchicine. Colchicine was maintained or resumed in six patients to prevent recurrence, with no further relapse. CONCLUSIONS: Colchicine may be safe and effective in treating SLE pericarditis and used as a steroids-sparing agent. These preliminary results need to be confirmed in a larger study with longer follow-up.


Subject(s)
Colchicine/administration & dosage , Gout Suppressants/administration & dosage , Lupus Erythematosus, Systemic/complications , Pericarditis/complications , Pericarditis/drug therapy , Adult , Antirheumatic Agents/therapeutic use , Echocardiography/methods , Electrocardiography/methods , Female , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Pericarditis/diagnostic imaging , Prednisone/administration & dosage , Prednisone/therapeutic use , Retrospective Studies , Treatment Outcome
2.
Praxis (Bern 1994) ; 88(42): 1726-30, 1999 Oct 14.
Article in French | MEDLINE | ID: mdl-10574039

ABSTRACT

Because of the adverse consequences of alcohol dependence on somatic, psychological and social functions, treatment of alcoholics always requires a multidisciplinary approach. It is a good example of a treatment network. Despite the numerous difficulties encountered in such a multidisciplinary approach, its beneficial effect, its efficacy and even its rewards are tremendously important. The alcohol treatment network of our region should permit such multidisciplinary therapies. Two clinical presentations are used to illustrate its virtues, but also some open questions.


Subject(s)
Alcoholism/rehabilitation , Patient Care Team , Alcoholism/psychology , Combined Modality Therapy , Humans , Male , Middle Aged , Switzerland
4.
J Stud Alcohol ; 57(6): 585-90, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8913988

ABSTRACT

OBJECTIVE: Evaluation of a French translation of the Addiction Severity Index (ASI) in 100 (78 male) alcoholic patients. METHOD: Validity of the instrument was assessed by measuring test-retest and interrater reliability, internal consistency and convergence and discrimination between items and scales. Concurrent validity was assessed by comparing the scores from the ASI with those obtained from three other clinimetric instruments. RESULTS: Test-retest reliability of ASI scores (after a 10-day interval) was good (r = 0.63 to r = 0.95). Interrater reliability was evaluated using six video recordings of patient interviews. Severity ratings assigned by six rates were significantly different (p < .05), but 72% of the ratings assigned by those who viewed the videos were within two points of the interviewer's severity ratings. Cronbach alpha coefficient of internal consistency varied from 0.58 to 0.81 across scales. The average item-to-scale convergent validity (r value) was 0.49 (range 0.0 to 0.84) for composite scores and 0.35 (range 0.00 to 0.68) for severity ratings, whereas discriminant validity was 0.11 on average (range-0.19 to 0.46) for composite scores and 0.12 (range-0.20 to 0.52) for severity ratings. Finally, concurrent validity with the following instruments was assessed: Severity of Alcoholism Dependence Questionnaire (40% shared variance with ASI alcohol scale), Michigan Alcoholism Screening Test (2% shared variance with ASI alcohol scale) and Hamilton Depression Rating Scale (31% shared variance with ASI psychiatric scale). CONCLUSIONS: The Addiction Severity Index covers a large scope of problems encountered among alcoholics and quantifies need for treatment. This French version presents acceptable criteria of reliability and validity.


Subject(s)
Alcoholism/classification , Severity of Illness Index , Adult , Female , Humans , Language , Male , Middle Aged , Observer Variation , Psychiatric Status Rating Scales , Psychometrics , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...